Jazz Pharmaceuticals (JAZZ) Q4 2024 earnings summary

Executive summary

• Achieved record total revenues of $4.1 billion in 2024, up 6% year-over-year, with Q4 revenue at nearly $1.1 billion, the highest ever.

• Xywav and Epidiolex revenues grew 16% and 15% year-over-year, respectively, in 2024; oncology revenues rose 9% to $1.1 billion.

• Advanced R&D pipeline with key milestones, including FDA approval and launch of Ziihera for second-line HER2-positive BTC and positive Phase III Zepzelca trial results.

• CEO transition planned, with ongoing commitment to strategic investments and growth.

• Generated $1.4 billion in cash from operations and ended 2024 with $3 billion in cash and investments.

Financial highlights

• 2024 total revenue grew 6% year-over-year to $4.1 billion; Q4 2024 revenue was nearly $1.1 billion, up 8% year-over-year.

• Non-GAAP adjusted net income for 2024 was $1.37 billion; adjusted EPS was $20.90, up 14% year-over-year.

• Operating cash flows totaled $1.4 billion in 2024; cash, cash equivalents, and investments totaled $3.0 billion at year-end.

• Xywav revenues grew 16% to $1.47 billion; Epidiolex revenues grew 15% to $972 million; oncology revenues grew 9% to $1.11 billion.

• Zepzelca revenues grew 11% to $320 million; Rylaze revenues grew 4% to $411 million.

Outlook and guidance

• 2025 revenue guidance: $4.15–$4.4 billion, representing 5% growth at midpoint.

• Adjusted net income expected at $1.4–$1.5 billion for 2025; adjusted EPS guidance: $22.50–$24.00.

• Gross margin expected at 88–92%; effective tax rate (GAAP) of (5)%–10%, non-GAAP 13–15%.

• Continued growth expected from Xywav, Epidiolex (blockbuster status), and Oncology portfolio.

• Modest Ziihera revenues expected in 2025 due to small BTC population; larger opportunity in GEA and breast cancer.